Sign up United Kingdom
Proactive Investors - Run By Investors For Investors

Silence Therapeutics plc defending its IP in the exciting gene silencing space

Speaking to Proactive's stocktube team, chief executive of Silence Therapeutics PLC (LON:SLN) Ali Mortazavi highlighted the progress the biotech firm has made and reiterated that, at its core, it was a drug development firm.
"We are trying to make novel drugs," he said, adding that the focus of its development products were on the human liver.
All biotech companies are made up of important intellectual property (IP) and its products, he added.
Relating to its IP, the firm is involved in some complex legal maneuverings, and it looks out for any company which starts to develop a drug in the RNA space, in which as yet no drug has approval. That's because it could potentially infringe on Silence’s IP.
An early example of a licensing deal came from Quark Pharmaceuticals, which licensed Silence’s technology ten years ago and is a partner with the group and has development drugs now in phase II and phase III clinical trials.
The two are currently however in arbitration over a $3mln milestone payment, which Silence believes it is owed.
Mortazavi pointed out however that this dispute has nothing to do with payments that will be due when and if the drugs are approved.
Earlier, in its interim results update, the firm revealed it will seek a partner for its flagship pancreatic cancer drug Atu027 following the release earlier this year of results from its phase II clinical trial.

Meet Faron Pharmaceuticals Ltd, Silence Therapeutics plc and Scancell Holdings Plc at our event, London , 01 November 2018. Register here »
View full SLN profile View Profile

Silence Therapeutics plc Timeline

No investment advice

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value or suitability of any particular security, portfolio of securities, transaction, investment strategy, or other matter.

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including company related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

© Proactive Investors 2018

Proactive Investors Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use